A randomized multicentre phase IfsI trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapRI-2

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Märten, Angela ^a,b   Schmidt, Jan ^a   Ose, Jennifer ^a,b   Harig, Sabine ^a,b   Abel, Ulrich ^a,b   Münter, Marc W ^a   Jäger, Dirk ^b   Friess, Helmut ^c   Mayerle, Julia ^d   Adler, Guido ^e   Seufferlein, Thomas ^f   Gress, Thomas ^g   Schmid, Roland ^c   Büchler, Markus W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; FLUOROURACIL; TUMOR MARKER; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; IMMUNOLOGICAL PARAMETERS; INTENSITY MODULATED RADIATION THERAPY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTPATIENT CARE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR RECURRENCE; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; PANCREAS TUMOR; PROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; INTERFERON ALFA-2B; MALE; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 67649295454     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-160     Document Type: Article

References (21)

1. Jemal A Siegel R Ward E Murray T Xu J Thun MJ Cancer statistics, 2007 CA: A cancer journal for clinicians 2007, 57(1):43-66. 10.3322/ canjclin.57.1.43 17237035
2. Neoptolemos J Stocken D Friess H Bassi C Dunn J Hickey H Beger H Fernandez-Cruz L Dervenis C Lacaine F et al The final results of the European Study Group for Pancreatic Cancer randomized controlled trial of adjuvant chemoradiotherapy and chemotherapy in patients with resectable pancreatic cancer New England Journal of Medicine 2004, 350:1200-1210. 10.1056/NEJMoa032295 15028824
3. Oettle H Post S Neuhaus P Gellert K Langrehr J Ridwelski K Schramm H Fahlke J Zuelke C Burkart C et al Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial Jama 2007, 297(3):267-277. 10.1001/jama.297.3.267 17227978
4. Adler G Seufferlein T Bischoff SC Brambs HJ Feuerbach S Grabenbauer G Hahn S Heinemann V Hohenberger W Langrehr JM et al [S3-Guidelines "Exocrine pancreatic cancer" 2007] Z Gastroenterol 2007, 45(6):487-523. 10.1055/s-2007-963224 17607616
5. Picozzi VJ Kozarek RA Traverso LW Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma Am J Surg 2003, 185(5):476-480. 10.1016/ S0002-9610(03)00051-5 12727570
6. Knaebel HP Märten A Schmidt J Hoffmann K Seiler C Lindel K Schmitz-Winnenthal H Fritz S Herrmann T Goldschmidt H et al Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma - CapRI: Study protocol [ISRCTN62866759] BMC Cancer 2005, 5(1):37. 1087479 15826316 10.1186/ 1471-2407-5-37
7. Linehan DC Tan MC Strasberg SM Drebin JA Hawkins WG Picus J Myerson RJ Malyapa RS Hull M Trinkaus K et al Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: A single-institution phase II study Ann Surg 2008, 248(2):145-151. 10.1097/SLA.0b013e318181e4e9 18650621
8. Picozzi J Abrams R Traverso L O'Reilly E Greeno E Martin R Wilfong L Decker P Pisters P Posner M ACOSOG Z05031: Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5- FU, and alpha-interferon ASCO: 2008; Chicago: J Clin Oncol 2008, 26.
9. Holsti LR Mattson K Niiranen A Standertskiold-Nordenstam CG Stenman S Sovijarvi A Cantell K Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung International journal of radiation oncology, biology, physics 1987, 13(8):1161-1166. 3038802
10. Kurzrock R Talpaz M Guttermann J Interferons: Clinical applications Philadelphia: Lippincott 1991.
11. Gutterman JU Cytokine therapeutics: Lessons from interferon alpha Proc Natl Acad Sci USA 1994, 91(4):1198-1205. 43124 8108387 10.1073/ pnas.91.4.1198
12. Zhu Y Tibensky I Schmidt J Ryschich E Marten A Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma J Immunother 2008, 31(7):599-606. 10.1097/ CJI.0b013e3181818769 18600184
13. Zhu Y Tibensky I Schmidt J Hackert T Ryschich E Jager D Buchler MW Marten A Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma J Immunother 2008, 31(1):28-33. 10.1097/ CJI.0b013e318157c682 18157009
14. Hoffmann K Mehrle S Schmidt J Buchler MW Marten A Interferon-alpha restitutes the chemosensitivity in pancreatic cancer Anticancer Res 2008, 28(3A):1499-1507. 18630504
15. Schmidt J Jäger D Hoffmann K Büchler MW Märten A Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): First data from the immunomonitoring J Immunother 2007, 30(1):108-115. 10.1097/01.cji.0000211317.15278.27 17198089
16. Schmidt J Patrut EM Ma J Jäger D Knaebel HP Büchler MW Märten A Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI) Cancer Immunol Immunother 2006, 55(11):1396-1405. 10.1007/s00262-006-0140-z 16485127
17. Ma JH Patrut E Schmidt J Knaebel HP Büchler MW Märten A Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma World J Gastroenterol 2005, 11(10):1521-1528. 15770730
18. Esposito I Kleeff J Bergmann F Reiser C Herpel E Friess H Schirmacher P Buchler MW Most pancreatic cancer resections are R1 resections Annals of surgical oncology 2008, 15(6):1651-1660. 10.1245/s10434-008-9839-8 18351300
19. Raraty MG Magee CJ Ghaneh P Neoptolemos JP New techniques and agents in the adjuvant therapy of pancreatic cancer Acta Oncol 2002, 41(7-8):582-595. 14651201
20. Klinkenbijl JH Jeekel J Sahmoud T van Pel R Couvreur ML Veenhof CH Arnaud JP Gonzalez DG de Wit LT Hennipman A et al Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group Ann Surg 1999, 230(6):776-782. discussion 782-774 1420941 10615932 10.1097/00000658-199912000-00006
21. Stocken DD Buchler MW Dervenis C Bassi C Jeekel H Klinkenbijl JH Bakkevold KE Takada T Amano H Neoptolemos JP Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer Br J Cancer 2005, 92(8):1372-1381. 10.1038/sj.bjc.6602513 15812554